Novel targeted therapies linked with the risk for melanoma and nonmelanoma skin cancer in PsA

Key clinical point: Adult patients with psoriatic arthritis (PsA) who received biologics, such as interleukin (IL)-12/23, IL-23, and IL-17 inhibitors, or small molecules, such as Janus kinase inhibitors, reported a risk for melanoma and nonmelanoma skin cancer (NMSC).

Major finding: In patients with PsA, the incidence rate of melanoma was 0.09 (95% CI 0.04-0.19) events per 100 patient years (PY) whereas that of NMSC was 0.47 (95% CI 0.28-0.81) events per 100 PY.

Study details: Findings are from a meta-analysis of 19 studies that included 13,739 patients with psoriasis and PsA who were treated with biologics or small molecules tested against an active or placebo comparator.

,

Disclosures: This study was funded by a research grant from Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland. P Brzewski declared receiving honoraria or consultation fees from various sources.

Source: Krzysztofik M et al. Risk of melanoma and nonmelanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: A systematic review and meta-analysis. Pharmaceuticals. 2023;17(1):14 (Dec 21). doi: 10.3390/ph17010014